Consolidated Capital Management LLC Boosts Stake in Eli Lilly and Company $LLY

Consolidated Capital Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 8,290 shares of the company’s stock after purchasing an additional 616 shares during the quarter. Eli Lilly and Company accounts for 2.3% of Consolidated Capital Management LLC’s investment portfolio, making the stock its 18th largest position. Consolidated Capital Management LLC’s holdings in Eli Lilly and Company were worth $6,462,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.4%

Shares of Eli Lilly and Company stock opened at $724.73 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The company has a market capitalization of $685.93 billion, a P/E ratio of 47.37, a P/E/G ratio of 1.01 and a beta of 0.47. The company has a 50 day moving average of $734.15 and a 200 day moving average of $766.82.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Morgan Stanley restated an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, Cantor Fitzgerald dropped their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.